Cargando…
Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies
Gene therapy is a revolutionary, cutting-edge approach to permanently ameliorate or amend many neuromuscular diseases by targeting their genetic origins. Motor neuron diseases and muscular dystrophies, whose genetic causes are well known, are the frontiers of this research revolution. Several geneti...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101723/ https://www.ncbi.nlm.nih.gov/pubmed/35563214 http://dx.doi.org/10.3390/ijms23094824 |
_version_ | 1784707157183168512 |
---|---|
author | Chamakioti, Myrsini Karantzelis, Nikolaos Taraviras, Stavros |
author_facet | Chamakioti, Myrsini Karantzelis, Nikolaos Taraviras, Stavros |
author_sort | Chamakioti, Myrsini |
collection | PubMed |
description | Gene therapy is a revolutionary, cutting-edge approach to permanently ameliorate or amend many neuromuscular diseases by targeting their genetic origins. Motor neuron diseases and muscular dystrophies, whose genetic causes are well known, are the frontiers of this research revolution. Several genetic treatments, with diverse mechanisms of action and delivery methods, have been approved during the past decade and have demonstrated remarkable results. However, despite the high number of genetic treatments studied preclinically, those that have been advanced to clinical trials are significantly fewer. The most clinically advanced treatments include adeno-associated virus gene replacement therapy, antisense oligonucleotides, and RNA interference. This review provides a comprehensive overview of the advanced gene therapies for motor neuron diseases (i.e., amyotrophic lateral sclerosis and spinal muscular atrophy) and muscular dystrophies (i.e., Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and myotonic dystrophy) tested in clinical trials. Emphasis has been placed on those methods that are a few steps away from their authoritative approval. |
format | Online Article Text |
id | pubmed-9101723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91017232022-05-14 Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies Chamakioti, Myrsini Karantzelis, Nikolaos Taraviras, Stavros Int J Mol Sci Review Gene therapy is a revolutionary, cutting-edge approach to permanently ameliorate or amend many neuromuscular diseases by targeting their genetic origins. Motor neuron diseases and muscular dystrophies, whose genetic causes are well known, are the frontiers of this research revolution. Several genetic treatments, with diverse mechanisms of action and delivery methods, have been approved during the past decade and have demonstrated remarkable results. However, despite the high number of genetic treatments studied preclinically, those that have been advanced to clinical trials are significantly fewer. The most clinically advanced treatments include adeno-associated virus gene replacement therapy, antisense oligonucleotides, and RNA interference. This review provides a comprehensive overview of the advanced gene therapies for motor neuron diseases (i.e., amyotrophic lateral sclerosis and spinal muscular atrophy) and muscular dystrophies (i.e., Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and myotonic dystrophy) tested in clinical trials. Emphasis has been placed on those methods that are a few steps away from their authoritative approval. MDPI 2022-04-27 /pmc/articles/PMC9101723/ /pubmed/35563214 http://dx.doi.org/10.3390/ijms23094824 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chamakioti, Myrsini Karantzelis, Nikolaos Taraviras, Stavros Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies |
title | Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies |
title_full | Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies |
title_fullStr | Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies |
title_full_unstemmed | Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies |
title_short | Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies |
title_sort | advanced gene-targeting therapies for motor neuron diseases and muscular dystrophies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101723/ https://www.ncbi.nlm.nih.gov/pubmed/35563214 http://dx.doi.org/10.3390/ijms23094824 |
work_keys_str_mv | AT chamakiotimyrsini advancedgenetargetingtherapiesformotorneurondiseasesandmusculardystrophies AT karantzelisnikolaos advancedgenetargetingtherapiesformotorneurondiseasesandmusculardystrophies AT taravirasstavros advancedgenetargetingtherapiesformotorneurondiseasesandmusculardystrophies |